Aldesleukin Clinical Trials

• Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients
  ClinicalTrials.gov Identifier: NCT00000821 - Active, not recruiting
  HIV Infections
  
• Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
  ClinicalTrials.gov Identifier: NCT00110812 - Recruiting
  HIV Infections
  
• Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00091104 - Active, not recruiting
  Melanoma (Skin)
  
• Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission
  ClinicalTrials.gov Identifier: NCT00534469 - Active, not recruiting
  Leukemia
  
• Chemotherapy Consisting of Fludarabine and Cyclophosphamide Followed By White Blood Cell Infusion, Vaccine Therapy, and Aldesleukin in Treating Patients With Recurrent or Refractory Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00084500 - Active, not recruiting
  Melanoma (Skin)
  
• Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00416429 - Active, not recruiting
  Kidney Cancer
  
• A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
  ClinicalTrials.gov Identifier: NCT00000849 - Active, not recruiting
  HIV Infections
  
• A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients with CD4 Counts Greater than 300 Cells/mm3
  ClinicalTrials.gov Identifier: NCT00000949 - Active, not recruiting
  HIV Infections
  
• An International Study to Evaluate Anti-HIV Therapy Plus Interleukin-2 (rIL-2) in HIV-Positive Patients
  ClinicalTrials.gov Identifier: NCT00004978 - Active, not recruiting
  HIV Infections
  
• Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
  ClinicalTrials.gov Identifier: NCT00002449 - Active, not recruiting
  HIV Infections
  
• Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy
  ClinicalTrials.gov Identifier: NCT00038259 - Active, not recruiting
  HIV Infections
  
• Treatment with Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
  ClinicalTrials.gov Identifier: NCT00000923 - Active, not recruiting
  HIV Infections
  
• Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients with CD4 Cell Counts of at Least 350 Cells/mm3
  ClinicalTrials.gov Identifier: NCT00000948 - Active, not recruiting
  HIV Infections
  
• The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients with CD4 Cell Counts of at Least 350 Cells/mm3
  ClinicalTrials.gov Identifier: NCT00000825 - Active, not recruiting
  HIV Infections
  
• A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients with CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy
  ClinicalTrials.gov Identifier: NCT00000909 - Active, not recruiting
  HIV Infections
  
• A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients with CD4 Cell Counts of at Least 350 Cells/mm3
  ClinicalTrials.gov Identifier: NCT00000889 - Active, not recruiting
  HIV Infections
  
• Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00250861 - Active, not recruiting
  Non-Hodgkin's Lymphoma
  
• Cyclophosphamide, Cellular Adoptive Immunotherapy, and Aldesleukin in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00438984 - Recruiting
  Melanoma (Skin)
  
• Cyclophosphamide or Cellular Adoptive Immunotherapy With or Without Aldesleukin in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00553306 - Recruiting
  Melanoma (Skin)
  
• Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00513604 - Recruiting
  Melanoma (Skin)
  
• Cyclophosphamide and Fludarabine Followed By Autologous Laboratory-Treated Peripheral Blood Lymphocytes and Aldesleukin in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00509288 - Recruiting
  Melanoma (Skin)
  
• Cyclophosphamide and Fludarabine Followed By Laboratory-Treated Donor Lymphocytes and High-Dose Aldesleukin in Treating Patients With Metastatic Melanoma That Did Not Respond to Previous Treatment
  ClinicalTrials.gov Identifier: NCT00537069 - Recruiting
  Melanoma (Skin)
  
• A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients
  ClinicalTrials.gov Identifier: NCT00002107 - Completed
  HIV Infections
  
• High-Dose Aldesleukin in Treating Patients With Metastatic or Unresectable Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00536757 - Recruiting
  Kidney Cancer
  
• Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00569296 - Recruiting
  Lung Cancer
  
• Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected with HIV
  ClinicalTrials.gov Identifier: NCT00006441 - Recruiting
  HIV Infections
  
• Chemotherapy and Total-Body Irradiation Followed By Autologous Lymphocyte Infusion, Aldesleukin, and Autologous Stem Cell Transplant in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00335127 - Recruiting
  Melanoma (Skin); Non-Melanomatous Skin Cancer
  
• Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients
  ClinicalTrials.gov Identifier: NCT00001131 - Recruiting
  HIV Infections
  
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin, and Umbilical Cord Blood Transplant in Treating Patients With Refractory Hematologic Cancers or Other Diseases
  ClinicalTrials.gov Identifier: NCT00354172 - Recruiting
  Leukemia; Myelodysplastic Syndromes
  
• Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00521261 - Recruiting
  Lymphoma
  
• A Phase I Study of the Safety of Proleukin (aldesleukin) in Combination with Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
  ClinicalTrials.gov Identifier: NCT00002321 - Completed
  Cytomegalovirus Retinitis; HIV Infections
  
• Phase II Trial Using Aldesleukin (lL-2) Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00118599 - Recruiting
  
  
• Cyclophosphamide and Fludarabine Followed By White Blood Cell Infusion and High-Dose Aldesleukin in Treating Patients With Metastatic Cancer That Overexpresses p53
  ClinicalTrials.gov Identifier: NCT00393029 - Recruiting
  Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
  
• Chemotherapy Followed By Autologous Natural Killer Cells and Aldesleukin in Treating Patients With Metastatic Melanoma or Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00354055 - Recruiting
  Kidney Cancer; Melanoma (Skin); Non-Melanomatous Skin Cancer
  
• Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children with Weakened Immune Systems
  ClinicalTrials.gov Identifier: NCT00006066 - Active, not recruiting
  HIV Infections
  
• The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
  ClinicalTrials.gov Identifier: NCT00554515 - Recruiting
  Metastatic Renal Cell Carcinoma
  
• Aldesleukin in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00331617 - Recruiting
  Kidney Cancer; Melanoma (Skin)
  
• Laboratory-Treated T Cells and Cyclophosphamide With or Without Aldesleukin in Treating Patients With HER2/Neu-Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With a HER2/Neu Vaccine
  ClinicalTrials.gov Identifier: NCT00228358 - Recruiting
  Breast Cancer; Lung Cancer; Ovarian Cancer
  
• Cytokine Working Group Phase II Study of Bevacizumab & IL-2 in Metastatic Renal Cancer Patients
  ClinicalTrials.gov Identifier: NCT00142142 - Recruiting
  Metastatic renal cell carcinoma
  
• A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection
  ClinicalTrials.gov Identifier: NCT00006154 - Not yet recruiting
  HIV Infections
  
• Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00414765 - Recruiting
  Metastatic Renal Cell Carcinoma; Metastatic Melanoma
  
• Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
  ClinicalTrials.gov Identifier: NCT00013663 - Completed
  HIV Infections
  
• A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC
  ClinicalTrials.gov Identifier: NCT00000680 - Completed
  HIV Infections
  
• Effect of Interleukin-2 on HIV Treatment Interruption
  ClinicalTrials.gov Identifier: NCT00015704 - Completed
  HIV Infections
  
• A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
  ClinicalTrials.gov Identifier: NCT00001005 - Completed
  HIV Infections
  
• Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients with Persistent Generalized Lymphadenopathy
  ClinicalTrials.gov Identifier: NCT00000728 - Completed
  HIV Infections
  
• Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
  ClinicalTrials.gov Identifier: NCT00006291 - Completed
  HIV Infections
  
• The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients with AIDS or AIDS Related Complex
  ClinicalTrials.gov Identifier: NCT00000986 - Completed
  HIV Infections
  
• A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
  ClinicalTrials.gov Identifier: NCT00000870 - Completed
  HIV Infections
  
• Safety and Effectiveness of Immunotherapy with Autologous HIV-Specific CD8 Cells in HIV Infected Adults
  ClinicalTrials.gov Identifier: NCT00110578 - Completed
  HIV Infections
  
• Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN alfa-2b), and Ribavirin (RBV) Treatment in Patients with Hepatitis C and HIV Coinfection
  ClinicalTrials.gov Identifier: NCT00015652 - Completed
  HIV Infections; Hepatitis C
  
• Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
  ClinicalTrials.gov Identifier: NCT00470015 - Suspended
  Melanoma (Skin)
  
• A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy
  ClinicalTrials.gov Identifier: NCT00000820 - Completed
  HIV Infections
  
• Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
  ClinicalTrials.gov Identifier: NCT00000875 - Terminated
  HIV Infections